More European HTA collaboration likely, but no EuroNICE
This article was originally published in SRA
Executive Summary
It seems likely that there will be more collaboration on healthcare technology assessments across the EU in a bid to reduce the 27 plus "hurdles to market access" following marketing approval1. However, a "EuroNICE" that would rule on cost-effectiveness for all member states is unlikely.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.